EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?

Yuanyuan Zhao, Ting Mei, Feifei Na, Xiaoman Tian, Rui Ao, Xiangyu Long, Qiang Luo, Ping Duan, Jiang Zhu, Yongsheng Wang, Meijuan Huang, Yongmei Liu und 1 weitere

Investigational New Drugs · 2024

DOI: 10.1007/s10637-024-01424-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Investigational New Drugs, 2024. Verfasst von Yuanyuan Zhao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Tumor Multidisciplinary Treatment, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University…. Hauptthemen laut MEDLINE: Lung Neoplasms, Pleural Effusion, Malignant, Adenocarcinoma of Lung. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 1·3·5 project for discipline of excellence, West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with metastatic lung adenocarcinoma (MLA) and malignant pleural effusion (MPE) without driver gene mutations have a poor prognosis. None of the standard treatment strategies is recommended for such patients. We retrospectively analyzed the efficacy of the first-line treatment for this specific population: standard platinum-based doublet chemotherapy (CT), CT plus an immune checkpoint inhibitor (CT plus ICI), and CT plus bevacizumab (CT plus Bev). A total of 323 eligible patients were enrolled: CT alone ( n = 166), CT plus Bev ( n = 72), and CT plus ICI ( n = 85). Treatment efficacy assessments were performed every two cycles according to the RECIST guidelines. The endpoints were overall survival (OS) and progression-free survival (PFS). Kaplan-Meier (K‒M) curves and the log-rank test were used to compare OS and PFS. p < 0.05 was the threshold of significance (statistical software: SPSS). The median follow-up was 11.4 months (range, 2.1–49.6 months). PFS and OS in the CT plus ICI/CT plus Bev cohort were significantly longer than those in the CT group (PFS: 7.8/6.4/3.9 months, p < 0.0001; OS: 16.4/15.6/9.6 months, p < 0.0001, respectively). CT plus Bev had better PFS and OS than CT plus ICI/CT in PD-L1 < 1% patients (PFS: 8.4/5.0/3.8 months, p < 0.0001; OS: 15.6/12.9/9.3 months, p < 0.0001). Among patients with PD-L1 1–49%, CT plus ICI led to a longer PFS and OS (PFS: 8.9/5.8/4.2 months, p = 0.009; OS: 24.2/18.8/11.5 months, p = 0.03). In the cohort with PD-L1 ≥ 50%, CT plus ICI was still the best first-line treatment (PFS: 19.7/13.8/9.6 months, p = 0.033; OS: 27.2/19.6/14.9 months, p = 0.047). In driver gene-negative MLA with MPE, CT plus Bev or ICI better controlled MPE and significantly prolonged survival compared to CT alone. PD-L1 expression (negative/positive) may be a key factor influencing the choice of CT plus Bev or ICI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsPleural Effusion, MalignantAdenocarcinoma of LungHumansBevacizumabImmune Checkpoint InhibitorsB7-H1 AntigenRetrospective Studies

Stichwörter der Autor:innen

Antiangiogenic agentCombined treatmentImmune checkpoint inhibitorsPD-L1 expressionPlatinum-based doublet chemotherapy

Substanzen

BevacizumabImmune Checkpoint InhibitorsB7-H1 Antigen

Autor:innen und Institutionen

  • Division of Thoracic Tumor Multidisciplinary Treatment, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
  • Department of Oncology, Chengdu Pidu District Hospital of Traditional Chinese Medicine, Chengdu, 611730, People's Republic of China.
  • Lung Cancer Center, West China Tianfu Hospital, Sichuan University, Chengdu, 610213, People's Republic of China.
  • Department of Oncology, Chengdu Jinniu District People's Hospital, Chengdu, 610031, People's Republic of China.
  • Department of Oncology, Sichuan Academy of Medical Sciences and Sichuan People's Hospital, Chengdu, 610072, People's Republic of China.
  • Department of Oncology, Sichuan Provincial Guang'An People's Hospital, Guang'An, 638500, People's Republic of China.

Förderung

  • 1·3·5 project for discipline of excellence, West China Hospital, Sichuan University

Zitieren

APA

Zhao, Y., Mei, T., Na, F., Tian, X., Ao, R., Long, X., Luo, Q., Duan, P., Zhu, J., Wang, Y., Huang, M., Liu, Y., & Gong, Y. (2024). First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01424-4

Vancouver

Zhao Y, Mei T, Na F, Tian X, Ao R, Long X, et al. First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01424-4

BibTeX
@article{Zhao2024,
  author = {Zhao, Yuanyuan and Mei, Ting and Na, Feifei and Tian, Xiaoman and Ao, Rui and Long, Xiangyu and Luo, Qiang and Duan, Ping and Zhu, Jiang and Wang, Yongsheng and Huang, Meijuan and Liu, Yongmei and Gong, Youling},
  title = {First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?},
  journal = {Investigational New Drugs},
  year = {2024},
  doi = {10.1007/s10637-024-01424-4}
}
Kostenlos starten →